1. Home
  2. RFL vs CRBU Comparison

RFL vs CRBU Comparison

Compare RFL & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rafael Holdings Inc. Class B

RFL

Rafael Holdings Inc. Class B

HOLD

Current Price

$2.00

Market Cap

133.1M

Sector

Finance

ML Signal

HOLD

Logo Caribou Biosciences Inc.

CRBU

Caribou Biosciences Inc.

HOLD

Current Price

$1.34

Market Cap

139.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RFL
CRBU
Founded
2017
2011
Country
United States
United States
Employees
N/A
97
Industry
Real Estate
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
133.1M
139.4M
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
RFL
CRBU
Price
$2.00
$1.34
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$10.75
AVG Volume (30 Days)
106.8K
1.1M
Earning Date
06-10-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
28.28
3.64
EPS
N/A
N/A
Revenue
$917,000.00
N/A
Revenue This Year
N/A
$1.63
Revenue Next Year
N/A
$10.93
P/E Ratio
N/A
N/A
Revenue Growth
43.96
N/A
52 Week Low
$1.12
$1.25
52 Week High
$3.96
$3.53

Technical Indicators

Market Signals
Indicator
RFL
CRBU
Relative Strength Index (RSI) 38.19 38.73
Support Level $1.86 N/A
Resistance Level $2.16 $1.72
Average True Range (ATR) 0.20 0.07
MACD -0.05 -0.01
Stochastic Oscillator 3.84 22.67

Price Performance

Historical Comparison
RFL
CRBU

About RFL Rafael Holdings Inc. Class B

Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.

About CRBU Caribou Biosciences Inc.

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.

Share on Social Networks: